[
  {
    "sentence": "The AKT2 gene 3′ UTR contains the SNP rs2304186, which, when mutated, prevents miRNA-4716–3p from binding (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The AKT2 gene 3′ UTR contains the SNP rs2304186, which, when mutated, prevents miRNA-4716–3p from binding (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "AKT2 gene association with blood cancer\nThe student t-test was applied for the statistical evaluation showed the relative AKT2 gene mRNA expression was significantly upregulated (p = 0.0034) in the patient's cohort compared to healthy individuals (Fig. 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "ANOVA-based analysis showed a non-significant downregulation of AKT2 gene expression in myeloma compared to leukemia and lymphoma (p = 0.3742) (Fig. 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The results revealed a significant upregulation of the AKT2 gene in AML patients (p = 0.0280) compared to ALL, CLL, and CML (Fig. 2C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The student t-test results revealed a non-significant upregulation of AKT2 gene expression in NHL patients (p = 0.7527) compared to HL patients (Fig. 2D).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The student t-test was applied for the statistical evaluation showed the relative AKT2 gene mRNA expression was significantly upregulated (p = 0.0034) in the patient's cohort compared to healthy individuals (Fig. 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "ANOVA-based analysis showed a non-significant downregulation of AKT2 gene expression in myeloma compared to leukemia and lymphoma (p = 0.3742) (Fig. 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The results revealed a significant upregulation of the AKT2 gene in AML patients (p = 0.0280) compared to ALL, CLL, and CML (Fig. 2C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The student t-test results revealed a non-significant upregulation of AKT2 gene expression in NHL patients (p = 0.7527) compared to HL patients (Fig. 2D).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Association of miRNA-4716–3p with blood cancer\nMicroRNA-4716–3p expression levels were significantly downregulated (p = 0.0294) in patients compared to healthy controls (Fig. 3A).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "ANOVA analysis showed that microRNA-4716–3p expression was non-significantly downregulated (p = 0.2637) in myeloma compared to leukemia and lymphoma (Fig. 3B).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In contrast to ALL, AML, and CML, microRNA-4716–3p expression showed a non-significant downregulation in CLL patients (p = 0.2137) (Fig. 3C).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "However, in lymphomas, there was significant downregulation (p = 0.0038) of microRNA-4716–3p expression in HL patients compared to NHL patients (Fig. 3D).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "MicroRNA-4716–3p expression levels were significantly downregulated (p = 0.0294) in patients compared to healthy controls (Fig. 3A).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "ANOVA analysis showed that microRNA-4716–3p expression was non-significantly downregulated (p = 0.2637) in myeloma compared to leukemia and lymphoma (Fig. 3B).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In contrast to ALL, AML, and CML, microRNA-4716–3p expression showed a non-significant downregulation in CLL patients (p = 0.2137) (Fig. 3C).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "However, in lymphomas, there was significant downregulation (p = 0.0038) of microRNA-4716–3p expression in HL patients compared to NHL patients (Fig. 3D).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "3.4. miRNA-4716–3p and AKT2 gene diagnostic value\nROC curve analysis was used to evaluate the diagnostic power of miRNA-4716–3p and its target AKT2 gene (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "ROC curve analysis was used to evaluate the diagnostic power of miRNA-4716–3p and its target AKT2 gene (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  }
]